Legal & Services

Bellevue Asset Management is an authorized manager of collective assets of collective investment schemes subject to regulation by the Swiss Financial Market Supervisory Authority FINMA. As such, it is in compliance with all regulatory and legal requirements placed upon managers of collective investment schemes. Bellevue Asset Management is responsible for the operating activities of BB Biotech AG and for the investment management operations of the Bellevue Funds (Lux) SICAV and other investment funds and mandates.

FINMA authorisation

Disclaimer / tax consequences of investment transactions

Investments can lose or gain in value. Past performance is not a guarantee of future performance. Potential investors should also obtain information about the potential tax consequences related to the purchase, ownership and sale of investment products at their place of domicile and seek advice from a tax specialist at their place of domicile. Please also take note of the brochure «Risks Involved in Trading Financial Instruments»​​​​​​​.

The Swiss Financial Services Act (FinSA)

Information for clients of Bellevue Asset Management AG

The Swiss Financial Services Act (FinSA) came into force on 1 January 2020. Its aims include strengthening investor protection and the Swiss financial centre, as well as creating comparable conditions for financial service providers. Most of the provisions will apply from January 2022 following a two-year transition period.

The FinSA essentially contains regulations on the provision of financial services and the offering of financial instruments and is intended to improve investor protection. In terms of content, the FIDLEG is closely aligned with the reforms of EU regulations and mainly covers the following areas:

- Optimisation of investor protection
- Transparency of financial products
- Revision of organisational requirements for the provision of services

FinSA concerns all financial services provided to clients domiciled in Switzerland or to clients abroad from Switzerland.

Bellevue Asset Management AG is a wholly owned subsidiary of Bellevue Group AG. Bellevue Asset Management AG is subject to the Financial Institutions Act (FinIA) and is supervised by the Swiss Financial Market Supervisory Authority (FINMA) as a manager of collective assets of collective investment schemes.

Contact Information Bellevue Asset Management AG

Bellevue Asset Management AG
Seestrasse 16
CH-8700 Küsnacht
Tel. +41 44 267 67 00
Fax +41 44 267 67 01
info(at)bellevue.ch

Contact information FINMA

Swiss Financial Market Supervisory Authority FINMA
Laupenstrasse 27
CH-3003 Bern
Tel. +41 31 327 91 00
Fax: +41 31 327 91 01
info(at)finma.ch

If you are not satisfied with our services, please get in touch with your contact person at Bellevue Asset Management AG. Alternatively, you can contact our Legal & Compliance department. The contact details are as follows:

Bellevue Asset Management AG
Legal & Compliance
Seestrasse 16
CH-8700 Küsnacht
Tel. +41 44 267 67 00
compliance(at)bellevue.ch

If we cannot find an amicable solution, you can contact the Swiss Financial Audit Office (FINOS), to which Bellevue Asset Management has affiliated itself. FINOS is a free and neutral information and mediation agency.

FINOS generally only becomes active after the client has confronted the manager of collective assets with the complaint in writing and the latter has had the opportunity to take a stand.

The contact details of FINOS are as follows:

Finanzombudsstelle Schweiz
Talstrasse 20
CH-8001 Zürich
Tel. domestic: 044 552 08 00
Tel. abroad: +41 44 552 08 00
www.finos.ch / info(at)finos.ch

Luxembourg investment funds

Bellevue Funds

RBC, Luxembourg, is responsible for fund administration, custodian services and order processing for our Luxembourg-based investment funds. We work with the following local partners in the markets where Bellevue funds are authorized for public distribution: 

Representative in Switzerland

ACOLIN Fund Services AG
Leutschenbachstrasse 50
CH-8050 Zürich

Paying agent in Switzerland

DZ Privatbank (Schweiz) AG
Münsterhof 12
Postfach 
CH-8022 Zürich

Main sales office

Bellevue Asset Management AG
Seestrasse 16
CH-8700 Küsnacht/Zürich 

Paying agent, information and distribution centre in Germany

ACOLIN (Europe) GmbH
Reichenaustrasse 11 a-c
D-78467 Konstanz

Paying agent, tax representative and information centre in Austria 

ERSTE BANK der oesterreichischen Sparkassen AG
Graben 21
A-1010 Wien

StarCapital Funds

DZ Privatbank S.A., is responsible for fund administration, custodian services and order processing for the StarCapital Luxembourg-based investment funds. We work with the following local partners : 

Representative and paying agent in Germany

DZ BANK AG 
Deutsche Zentral-Genossenschaftsbank 
Frankfurt am Main Platz der Republik
D-60265 Frankfurt am Main

Representative in Germany

StarCapital AG
Kronberger Straße 45
D-61440 Oberursel

Representative and paying agent in Austria

ERSTE BANK DER OESTERREICHISCHEN SPARKASSEN AG
Am Belvedere 1
1100 Wien

Representative in Switzerland

IP Concept (Schweiz) AG
In Gassen 6, PO Box
CH-8022 Zurich

Paying agent in Switzerland

DZ Privatbank (Schweiz) AG
Münsterhof 12, PO Box, 
CH- 8022 Zurich 

Purchase & Redemption

Our Luxembourg investment funds are traded on a daily basis. You can invest in Bellevue funds through your house bank or broker by giving the corresponding securities identification number (security number or ISIN) with your order.

Our funds are traded without any mark-up to Net Asset Value (NAV). Bellevue Asset Management does not charge a special commission on the purchase or redemption of fund units. A transaction fee might be charged by your house bank or broker.

We attach great importance to transparency and provide our clients with prompt, comprehensive information. Information on the prices of our funds can be found in the following newspapers published in Switzerland, Germany and Austria and on the following financial portals: 

Here institutional investors and financial intermediaries will find detailed information on administrative procedures and contact details in connection with the purchase and sale of fund units

ReportPDF
Subscription/Redeption FlowPDF
Overview securities numbersPDF
UK Investor reportPDF
Information from 25.10.2011PDF
Bylaws PDF
Information from April 7, 2015PDF
Information from April 17,2015PDF
Information from May 6,2015PDF
Contact personsPDF
Payment instructionsPDF

 

Swiss Investment Fund

Fund Management Company BB Entrepreneur Switzerland

PMG Fonds Management AG
Sihlstrasse 95
8001 Zürich 

BB Adamant Funds

Swisscanto Fondsleitung AG
Bahnhofstrasse 9
8001 Zürich 

Custodian BB Entrepreneur Switzerland

RBC Investor Services Bank S.A.
Esch-sur-Alzette
Zweigniederlassung Zürich
Badenerstrasse 567
Postfach 101
CH-8066 Zürich

BB Adamant Funds

Zürcher Kantonalbank
Geschäftshaus Hard A
Postfach
8010 Zürich 

We offer investment funds under Swiss law that are traded daily. You can invest in the funds at any time through your house bank or broker by giving the corresponding securities identification number (security number or ISIN) with your order.

The funds are traded without any mark-up to Net Asset Value (NAV). Bellevue Asset Management does not charge a special commission on the purchase or redemption of fund units. A transaction fee might be charged by your house bank or broker..

We attach great importance to transparency and provide our clients with prompt, comprehensive information. Information on fund prices can be found in the following daily and financial newspapers in Switzerland and on the following financial portals: 

  • NZZ
  • Finanz & Wirtschaft
  • www.fundinfo.com
  • www.zkb.ch Bloomberg
  • Reuters
  • Telekurs 

Here institutional investors and financial intermediaries will find detailed information on administrative procedures and contact persons in connection with the purchase and sale of fund units: 

ReportPDF
Identification numbersPDF
Contact personsPDF

 

Investment Company

BB Biotech AG is a corporation listed on the SIX Swiss Exchange, in Germany (Prime Standard) and the "Segmento Star" in Italy and is domiciled in Schaffhausen, Schwertstrasse 6. Its business purpose is to invest in biotechnology companies. Asset management, administration and marketing responsibilities have been entrusted to Bellevue Group since the company was founded. 

The Board of Directors of BB Biotech AG consists of highly reputable and experienced industry professionals and scientists: 

  • Dr. Erich Hunziker, Chairman of the Board of Directors
  • Dr. Clive Meanwell, Member of the Board of Directors
  • Dr. Thomas von Planta, Member of the Board of Directors
  • Prof. Dr. Mads Krogsgaard Thomsen, Member of the Board of Directors

For more information on BB Biotech please visit our website www.bbbiotech.com

Private Equity

The venture capital products were established under Guernsey law. Please contact us for information.

Bellevue Asset Management AG
Seestrasse 16 / Postfach
CH-8700 Küsnacht
Tel. +41 (0)44 267 67 00
Fax +41 (0)44 267 67 01
info(at)bellevue.ch  

Tax information

Fund nameLegal formRegulatory statusDE Investmentsteuergesetz (InvStG)AT Investmentfondsgesetz (InvFG)
BB Adamant Asia Pacific HealthcareSICAVUCITSTransparentKESt-Meldefonds
BB Adamant BiotechSICAVUCITSTransparentKESt-Meldefonds
BB Adamant Digital HealthSICAVUCITSTransparentKESt-Meldefonds
BB Adamant Emerging Markets HealthcareSICAVUCITSTransparentKESt-Meldefonds
BB Adamant Healthcare StrategySICAVUCITSTransparentKESt-Meldefonds
BB Adamant Medtech & ServicesSICAVUCITSTransparentKESt-Meldefonds
BB Adamant Sustainable HealthcareSICAVUCITSTransparentKESt-Meldefonds
BB African OpportunitiesSICAVUCITSTransparentKESt-Meldefonds
BB Entrepreneur EuropeSICAVUCITSTransparentKESt-Meldefonds
BB Entrepreneur Europe SmallSICAVUCITSTransparentKESt-Meldefonds
BB Entrepreneur Swiss Small & MidSICAVUCITSTransparentKESt-Meldefonds
BB Global MacroSICAVUCITSTransparentKESt-Meldefonds
BB Europe Equity Market NeutralSICAVUCITSTransparentKESt-Meldefonds
BB Entrepreneur SwitzerlandSchweizer FondsKAG-
BB Adamant Global BiotechSchweizer FondsKAG
BB Adamant Global Healthcare IndexSchweizer FondsKAG
BB Adamant Global Medtech & Services Schweizer FondsKAG

Information about the registration in the respective countries can be found in the current Prospectus.